Detail

Study ID: AstraZeneca D933QC00001 ADRIATIC

Title:

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Description:
Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell- Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Description: You are invited to take part in this research study because you have been diagnosed with a type of lung cancer - limited stage, small cell lung cancer (LS-SCLC), that cannot be removed by surgery. The reason for the study is to investigate effective consolidation treatment after standard concurrent chemotherapy and radiation therapy for this type of cancer. Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. New drugs are being developed to increase the immune system response. Two such drugs are durvalumab and tremelimumab. AstraZeneca AB is doing this research to find out if the medications called durvalumab and tremelimumab will work, and be safe for the treatment of LS-SCLC.
Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Christopher Sumey, MD,Amit Panwalkar, MD
Disease:
Small Cell Lung Cancer
Stage:
Phase III
Status:
Active - Open to Accrual